X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Indoco Remedies with Ingersoll Rand - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

INDOCO REMEDIES vs INGERSOLL RAND - Comparison Results

INDOCO REMEDIES    Change

Indoco Remedies is engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs) for domestic as well as the international markets. The company's focus areas include anti-infective, respiratory, anti-diabetic... More

INGERSOLL RAND 
   Change

Ingersoll Rand is a global diversified industrial company, engaged in the business of providing solutions for infrastructure development, industrial solutions, residential solutions and security technologies. Ingersoll-Rand manufactures a wide range ... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    INDOCO REMEDIES INGERSOLL RAND INDOCO REMEDIES/
INGERSOLL RAND
 
P/E (TTM) x 86.0 17.9 481.7% View Chart
P/BV x 3.1 1.5 201.9% View Chart
Dividend Yield % 0.7 1.1 66.8%  

Financials

 INDOCO REMEDIES   INGERSOLL RAND
EQUITY SHARE DATA
    INDOCO REMEDIES
Mar-17
INGERSOLL RAND
Mar-18
INDOCO REMEDIES/
INGERSOLL RAND
5-Yr Chart
Click to enlarge
High Rs360940 38.3%   
Low Rs249652 38.2%   
Sales per share (Unadj.) Rs119.0194.7 61.1%  
Earnings per share (Unadj.) Rs8.428.2 29.7%  
Cash flow per share (Unadj.) Rs15.232.1 47.4%  
Dividends per share (Unadj.) Rs1.606.00 26.7%  
Dividend yield (eoy) %0.50.8 69.6%  
Book value per share (Unadj.) Rs70.7357.5 19.8%  
Shares outstanding (eoy) m92.1531.57 291.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.64.1 62.6%   
Avg P/E ratio x36.428.3 128.9%  
P/CF ratio (eoy) x20.024.8 80.8%  
Price / Book Value ratio x4.32.2 193.6%  
Dividend payout %19.121.3 89.8%   
Avg Mkt Cap Rs m28,08325,128 111.8%   
No. of employees `0006.00.7 869.7%   
Total wages/salary Rs m2,1671,061 204.2%   
Avg. sales/employee Rs Th1,817.08,858.6 20.5%   
Avg. wages/employee Rs Th359.01,528.8 23.5%   
Avg. net profit/employee Rs Th127.71,280.8 10.0%   
INCOME DATA
Net Sales Rs m10,9686,148 178.4%  
Other income Rs m40714 5.6%   
Total revenues Rs m11,0076,862 160.4%   
Gross profit Rs m1,565708 221.1%  
Depreciation Rs m633126 502.2%   
Interest Rs m62-21 -298.6%   
Profit before tax Rs m9091,317 69.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m139428 32.4%   
Profit after tax Rs m771889 86.7%  
Gross profit margin %14.311.5 123.9%  
Effective tax rate %15.332.5 47.0%   
Net profit margin %7.014.5 48.6%  
BALANCE SHEET DATA
Current assets Rs m5,7259,916 57.7%   
Current liabilities Rs m5,4541,593 342.4%   
Net working cap to sales %2.5135.4 1.8%  
Current ratio x1.06.2 16.9%  
Inventory Days Days6246 134.7%  
Debtors Days Days7265 109.9%  
Net fixed assets Rs m5,3071,220 435.2%   
Share capital Rs m184316 58.4%   
"Free" reserves Rs m6,33110,969 57.7%   
Net worth Rs m6,51611,285 57.7%   
Long term debt Rs m1,3230-   
Total assets Rs m11,97012,888 92.9%  
Interest coverage x15.6-62.3 -25.1%   
Debt to equity ratio x0.20-  
Sales to assets ratio x0.90.5 192.1%   
Return on assets %7.06.7 103.3%  
Return on equity %11.87.9 150.2%  
Return on capital %12.411.5 107.9%  
Exports to sales %024.4 0.0%   
Imports to sales %020.7 0.0%   
Exports (fob) Rs mNA1,502 0.0%   
Imports (cif) Rs mNA1,275 0.0%   
Fx inflow Rs m4,5071,502 300.0%   
Fx outflow Rs m1,1411,574 72.5%   
Net fx Rs m3,366-72 -4,680.8%   
CASH FLOW
From Operations Rs m886771 114.9%  
From Investments Rs m-1,706935 -182.4%  
From Financial Activity Rs m1,316-231 -569.8%  
Net Cashflow Rs m4971,475 33.7%  

Share Holding

Indian Promoters % 59.2 0.0 -  
Foreign collaborators % 0.0 74.0 -  
Indian inst/Mut Fund % 12.5 7.2 173.6%  
FIIs % 6.0 0.5 1,200.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.4 18.3 122.4%  
Shareholders   12,805 19,522 65.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare INDOCO REMEDIES With:   GEOJIT FINANCIAL SERVICES  GREENPLY IND  NESCO LIMITED  IIFL HOLDINGS  KOTHARI PRODUCTS  



Today's Market

Sensex Opens Strong; PSU & Realty Stocks Lead(09:30 am)

Asian stock markets are higher today as Japanese and Hong Kong shares show gains. The Nikkei 225 is up 1% while the Hang Seng is up 1.3%.

Related Views on News

INDOCO REMEDIES Announces Quarterly Results (2QFY19); Net Profit Down 139.4% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, INDOCO REMEDIES has posted a net profit of Rs 78 m (down 139.4% YoY). Sales on the other hand came in at Rs 2 bn (down 17.3% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

INGERSOLL RAND Announces Quarterly Results (2QFY19); Net Profit Up 2.0% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, INGERSOLL RAND has posted a net profit of Rs 225 m (up 2.0% YoY). Sales on the other hand came in at Rs 2 bn (up 10.1% YoY). Read on for a complete analysis of INGERSOLL RAND's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

INDOCO REMEDIES SHARE PRICE


Dec 13, 2018 11:13 AM

TRACK INDOCO REMEDIES

  • Track your investment in INDOCO REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON INDOCO REMEDIES

INDOCO REMEDIES - FINOLEX IND. COMPARISON

COMPARE INDOCO REMEDIES WITH

MARKET STATS